Latest Advances in Lung Cancer Research

Researchers developed RARE-seq, an ultrasensitive blood test detecting cell-free RNA that identifies early-stage lung cancer and monitors treatment resistance.

A new JAMA review shows that small cell lung cancer, which affects 95% smokers and has only 12-30% five-year survival, is seeing breakthrough improvements with immunotherapy extending survival to 56 months for early-stage disease, though advanced cases remain challenging with most patients relapsing within three months.

New hope for small cell lung cancer patients as the first patient receives Peluntamig in a clinical trial. This experimental drug targets specific cancer growth pathways.

New drug shrinks HER2-mutant lung cancer tumors in 73% of patients, offering hope for improved treatment options.

Comprehensive review examining molecular mechanisms of cancer invasion and metastasis, identifying potential therapeutic targets for preventing cancer spread.

Final clinical trial results demonstrate selpercatinib’s safety and efficacy in treating RET fusion-positive non-small cell lung cancer patients.

RYBREVANT and LAZCLUZE combination shows significant overall survival benefit in EGFR-mutated NSCLC patients, exceeding one year median survival improvement over standard osimertinib treatment.

Neoadjuvant chemotherapy before surgery significantly improves survival in stage IIIA NSCLC, reducing death risk by 30% and increasing 5-year survival to 41% from 26%.

Osimertinib after surgery significantly improves survival in early-stage EGFR-mutated NSCLC, reducing cancer recurrence and offering a new standard of care.

Dr. David Carbone at Ohio State advances lung cancer treatment with immunotherapy and targeted therapies, providing compassionate, personalized care and hope to patients.

FDA approves Opdivo for early-stage NSCLC. This immunotherapy can be used before and after surgery, potentially improving outcomes for patients with resectable lung cancer.

At WCLC, experts highlighted various side effects of lung cancer treatments, emphasizing thyroid, skin, eye, and lung complications. They stressed the importance of early detection and proactive management for better patient outcomes.